Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Perez Fidalgo, Alejandro
298  Ergebnisse:
Personensuche X
?
1

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A phase III, randomized,..:

Vergote, Ignace ; Perez Fidalgo, Alejandro ; Valabrega, Giorgio...
International Journal of Gynecologic Cancer.  34 (2024)  8 - p. 1283-1289 , 2024
Link: https://doi.org/10.1136/..
 
?
2

Cost-effectiveness of olaparib plus bevacizumab versus beva..:

Cedillo, Sergio ; Garí, Carla ; Aceituno, Susana...
International Journal of Gynecologic Cancer.  34 (2023)  2 - p. 277-284 , 2023
Link: https://doi.org/10.1136/..
 
?
3

Treatment of cervical cancer: the importance of a multidisc..:

Pérez Fidalgo, J. Alejandro ; Hernández Machancoses, Ana ; Martín González, Víctor.
Clinical and Translational Oncology.  13 (2011)  7 - p. 431-433 , 2011
Link: https://doi.org/10.1007/..
 
?
4

Primary results and characterization of patients with excep..:

Mutch, David ; Voulgari, Athina ; Chen, Xian (Marissa)...
Cancer.  130 (2024)  11 - p. 1940-1951 , 2024
Link: https://doi.org/10.1002/..
 
?
5

An Open-label Phase I Study of GDC-0927 in Postmenopausal W..:

Chandarlapaty, Sarat ; Dickler, Maura N. ; Perez Fidalgo, Jose Alejandro...
Clinical Cancer Research.  29 (2023)  15 - p. 2781-2790 , 2023
Link: https://doi.org/10.1158/..
 
?
6

Aurora kinase inhibitors: a new class of drugs targeting th..:

Pérez Fidalgo, José Alejandro ; Roda, Desamparados ; Roselló, Susana..
Clinical and Translational Oncology.  11 (2009)  12 - p. 787-798 , 2009
Link: https://doi.org/10.1007/..
 
?
7

ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, pla..:

Makker, Vicky ; Vergote, Ignace ; Mirza, Mansoor...
Gynecologic Oncology.  176 (2023)  - p. S156 , 2023
Link: https://doi.org/10.1016/..
 
?
8

SEOM-GEICO clinical guidelines on endometrial cancer (2021):

Barretina-Ginesta, María Pilar ; Quindós, María ; Alarcón, Jesús Damián...
Clinical and Translational Oncology.  24 (2022)  4 - p. 625-634 , 2022
Link: https://doi.org/10.1007/..
 
?
9

UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab..:

Richardson, Debra ; Marth, Christian ; Banerjee, Susana...
Gynecologic Oncology.  166 (2022)  - p. S284 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Prospective evaluation of the conversion rate in the recept..:

de Dueñas, Eduardo Martínez ; Hernández, Ana Lluch ; Zotano, Ángel Guerrero...
Breast Cancer Research and Treatment.  143 (2014)  3 - p. 507-515 , 2014
Link: https://doi.org/10.1007/..
 
?
11

SEOM–GEICO clinical guideline on epithelial ovarian cancer ..:

Perez-Fidalgo, Jose Alejandro ; Gálvez-Montosa, Fernando ; Guerra, Eva María...
Clinical and Translational Oncology.  , 2024
Link: https://doi.org/10.1007/..
 
?
12

Atezolizumab plus bevacizumab and chemotherapy for metastat..:

Oaknin, Ana ; Gladieff, Laurence ; Martínez-García, Jerónimo...
The Lancet.  403 (2024)  10421 - p. 31-43 , 2024
Link: https://doi.org/10.1016/..
 
?
13

Long-term follow-up of efficacy and safety of selinexor mai..:

Makker, Vicky ; Perez-Fidalgo, Jose Alejandro ; Valabrega, Giorgio...
Gynecologic Oncology.  185 (2024)  - p. 202-211 , 2024
Link: https://doi.org/10.1016/..
 
?
14

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor..:

Leary, Alexandra ; Estévez-García, Purificación ; Sabatier, Renaud...
BMC Cancer.  24 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
15

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mT..:

Leary, Alexandra ; Estévez-García, Purificación ; Sabatier, Renaud...
BMC Cancer.  24 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
1-15